细胞周期蛋白依赖性激酶4/6抑制剂与血栓栓塞事件的关联性分析OA
Analysis of Correlation between Cyclin-dependent Kinase 4/6 Inhibitors and Thromboembolism events
目的 挖掘和评价细胞周期蛋白依赖性激酶 4/6(CDK4/6)抑制剂与血栓栓塞事件之间的关联性,为临床安全用药提供借鉴和参考.方法 通过OpenVigil 2.1 药物警戒分析工具提取美国食品药品监督管理局不良事件报告系统(FAERS)数据库中CDK4/6 抑制剂相关血栓栓塞事件,提取时间截至2024 年12 月31 日.利用报告比值比法(ROR)和比例报告比值法(PRR)进行血栓栓塞事件信号分析.结果 共检索到CDK4/6 抑制剂相关血栓栓塞事件1516 份,哌柏西利、阿贝西利、瑞博西尼分别为984、228、304份,其中肺栓塞事件最多,占所有血栓栓塞事件的59.83%(907/1516).37.34%(566/1516)CDK4/6 抑制剂相关血栓栓塞事件发生于18~64 岁,45.78%(694/1516)发生于65~85 岁.在性别构成上,女性高于男性.信号结果显示肺栓塞在 3 种CDK4/6 抑制剂中均可生成可疑信号,强度排序为阿贝西利>瑞博西尼>哌柏西利.结论 哌柏西利、阿贝西利、瑞博西尼 3 种CDK4/6 抑制剂均与血栓栓塞事件存在关联性,医务人员应加强CDK4/6 抑制剂用药监测,警惕血栓栓塞事件的发生.
Objective To explore and evaluate the association between cyclin-dependent kinase 4/6(CDK4/6)inhibitors and thromboembolic events,so as to provide reference for clinical safety of drug use.Methods Using the OpenVigil 2.1 pharmacovigilance analysis tool,thromboembolic events related to CDK4/6 inhibitors in the US Food and Drug Administration's Adverse Event Reporting System(FAERS)database were extracted.The extraction period ended on December 31,2024.Signal analysis of thromboembolic events was conducted using the report odds ratio method(ROR)and the proportion report ratio method(PRR).Results A total of 1516 thromboembolic events related to CDK4/6 inhibitors were retrieved,of which 984,228,304 were identified by palbociclib,abemaciclib and ribociclib,respectively.Pulmonary embolic events were the most common,accounting for 59.83%(907/1516)of all thromboembolic events.37.34%(566/1516)of CDK4/6 inhibitor-related thromboembolism events occurred in 18-64 years of age,45.78%(694/1516)in 65-85 years of age.In terms of gender composition,women are higher than men.The signal results showed that pulmonary embolism produced suspicious signals in all three CDK4/6 inhibitors,and the intensity was ranked as abemaciclib>ribociclib>palbociclib.Conclusion This study identified a significant association between all three CDK4/6 inhibitors(palbociclib,abemaciclib,and ribociclib)and thromboembolic events.Clinicians should implement rigorous monitoring protocols to mitigate the risk of thromboembolic ADEs.
韦剑发
河池市人民医院药学部,广西 河池 547000
医药卫生
细胞周期蛋白依赖性激酶4/6抑制剂血栓栓塞不良反应信号挖掘
Cyclin-dependent kinase 4/6 inhibitorsThromboembolismAdverse reactionsSignal mining
《中国药物经济学》 2026 (6)
87-91,5
评论